8-K/A
filed April 3, 2025, 7:59 PM ET
CIK 0001708331
regulatory
confidence high
sentiment negative
materiality 1.00
Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax receives Nasdaq delisting notice; all independent directors and CFO resign
Virpax Pharmaceuticals, Inc.
- Nasdaq panel delists Virpax for failing minimum stockholders' equity; trading suspended April 4, 2025.
- Company will not appeal; delisting effective after SEC Form 25 filing.
- Four directors (Randhawa, Deol, Su, Field) resigned effective April 2, 2025.
- Katharyn Field also resigned as VP; Usama Chaudhry resigned as CFO, same date.
- Resignations not due to any disagreement with company per filing.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.98
Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Esha Randhawa resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Usama Chaudhry resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
On the same date, Ms. Field also resigned from her position as Vice President, and Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, each effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Judy Su resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charn Deol resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Katharyn Field resigned as Vice President at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Vice President
Exact text from the filing
On the same date, Ms. Field also resigned from her position as Vice President, and Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, each effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Katharyn Field resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.